- Chemical Engineering
- Food Science
- Medical Devices
- Metallurgy & Ceramics
- Pharmaceuticals & Pharmaceutical Formulation
- Polymer & Materials Science
- Design Patents Practice
- Due Diligence in IP Acquisitions
- IP Transactional
- Patent Landscaping and Risk Analysis
- Pharmaceutical IP Services
- Post Grant Practice
- Strategic IP Portfolio Development and Management
- Trade Secrets
- Supreme Court of the United States, 1999
- Court of Appeals for the Federal Circuit, 1994
- Court of Appeals for the First Circuit, 1994
- U.S. District Court, District of Connecticut, 1998
- U.S. District Court, District of Massachusetts, 1994
- State of Connecticut, 1998
- Commonwealth of Massachusetts, 1994
- U.S. Patent and Trademark Office, 1994
New England School of Law, J.D., 1994
Washington State University, Ph.D., Biochemistry, 1991
Washington State University, M.S., Biochemistry, 1988
UCLA, B.S. Biochemistry, 1985
- Adjunct Professor of Law, Quinnipiac University School of Law, lecturing on intellectual property and healthcare, 2017-present
Todd Garabedian, Ph.D. has extensive experience as an intellectual property attorney in a wide variety of disciplines related to the biological and chemical sciences, including chemistry, biochemistry, organic chemistry, pharmaceuticals, molecular biology, and materials science. Todd began his professional career as a research biochemist at the UCLA School of Medicine and thereafter at Washington State University where he worked in a variety of biological fields mainly centered around protein structure, function, and characterization. Before joining Cantor Colburn, Todd was a Partner at Wiggin and Dana LLP, advising clients in all aspects of patent law in the chemical and life science arts, including patent application preparation, prosecution, counseling, portfolio management, and legal opinions. His experience extends to trademarks, copyrights, trade secrets, and corporate transactions relating to intellectual property assets, including acquisitions, joint ventures, licensing, and other technology transfer transactions.
Partner, Cantor Colburn LLP, 2013-present
Partner, Wiggin & Dana LLP, New Haven, CT, 2003-2013
Of Counsel, Wiggin and Dana LLP, New Haven, CT, 2002-2003
Associate, Wiggin and Dana LLP, New Haven, CT, 1996-2002
Associate, Weingarten, Schurgin, Gagnebin & Hayes, Boston, MA, 1994-1996
- U.S. Patent Counsel, Affibody AB, Solna, Sweden
- U.S. Patent Counsel, Karo Bio AB, Huddinge, Sweden
- IP Counsel, MicroChem Corp, Newton, MA
Court Reviews Patentable Subject Matter in Biosciences, Connecticut Law Tribune
U.S. Patent and Trademark Office Clarifies its Rules on Small Entity Qualifications, TerraLex Intellectual Property Newsletter, 11th Edition, April 2005
Managing The University Patent Portfolio And Making It Attractive To Licensees: A Commonsense Approach, Research Management Review, Volume 14, Number 2, Spring 2005
Public PAIR and Assignments on the Web Database Systems: The Newest Tools to Monitor the Filing, Prosecution, and Ownership of United States Patent Applications, TerraLex Intellectual Property Newsletter, 10th Edition, October, 2004
Erroneous Small Entity Designation Can Jeopardize Patent Rights, TerraLex Intellectual Property Newsletter, 9th Edition, April, 2004
Recent Developments in Intellectual Property Law: Avoiding Traps in the Pursuit of University Research, Research Management Review, Winter/Spring 2003
Nontraditional Publications and Their Effect on Patentable Inventions, Nature Biotechnology, Volume 20, Number 4, pages 401-402 (2002)
Recent Changes to the US Patent Laws: Their Effect on Inventions in Biotechnology, TerraLex Intellectual Property Newsletter, 7th Edition, February/March, 2002
Laboratory Record Keeping, Reprinted with permission from Nature Biotechnology v. 15 (August 1997) pp.799-800.
Garabedian TE and Yount RG, Direct photoaffinity labeling of gizzard myosin with vanadate-trapped adenosine diphosphate. Biochemistry (1991) 30:10126.
Garabedian TE and Yount RG, Direct photoaffinity labeling of gizzard myosin with [3H]uridine diphosphate places Glu185 of the heavy chain at the active site. J. Biol. Chem. (1990) 265:22547-53.
- September 12, 2016
- September 18, 2013
Cantor Colburn LLP, one of the country’s leading intellectual property (IP) law firms, announced the hiring of partner Todd E. Garabedian, Ph.D., formerly a partner at Wiggin & Dana LLP. Garabedian, a Ph.D. biochemist, has almost 20 years of extensive experience in patent application preparation, prosecution, counseling, portfolio management, and legal opinions in a wide variety of disciplines related to the biological and chemical sciences.
- January 24, 2017Alexandria, Virginia
With the first four U.S. biosimilars approved and many more in the FDA pipeline, it is critical that pharmaceutical companies develop strategies at a business operations level to comply with evolving regulations, mitigate risk and execute long-term decisions to prepare for success. At the 12th Biosimilars Summit, industry experts will speak about the tools and strategies needed to prepare for the impending changes impacting all elements of the healthcare industry.
- October 26, 2016Farmington, Connecticut
The 2016 Forum on Healthcare Innovation is presented by The Jackson Laboratory in collaboration with the Connecticut Health Council. The Forum will focus on two specific topics: coverage decisions for biomedical innovation and emerging science and technology that will change the future of healthcare.
- September 28, 2016Anlyan Center at Yale University, New Haven, Connecticut
CURE presents a deeply experienced panel of bioscience investors as they explain the venture capital trends of 2016 as well as discuss a look into the future as to where the capital will be flowing in 2017.
- July 6, 2016Okinawa, Japan
Todd Garabedian, Ph.D. will present a seminar entitled, "Patent Law as a Career Path" at the Okinawa Institute of Science and Technology in Okinawa, Japan on July 6, 2016. Todd will discuss his career in patent law, as well as recent changes in patent law, including the importance of legal protection for novel intellectual assets that could have commercial implications.
- June 6, 2016San Francisco, California
- June 4, 2015Hartford, Connecticut
3D Printing: Living Tissue to Human Organ, UConn's first Science Salon event, takes place Thursday, June 4, 2015 at NIXS Hartford at 6 p.m. The discussion will explore this transformational innovation from a variety of perspectives, namely medical, ethical, economic and technical.
- April 25, 2015Hartford, Connecticut
Cantor Colburn is proud to be a returning sponsor of the UConn Health White Coat Gala.
- April 15, 2015New Haven, Connecticut
Cantor Colburn partner Todd Garabedian, Ph.D. will speak at the University of New Haven as part of their Alvine Engineering Professional Effectiveness and Enrichment Program, Spring 2015, Speaker Series.
- Yale & CURE BioHaven present Challenges Facing Pharmaceutical R&DSeptember 10, 2014Anlyan Center at Yale, New Haven, Connecticut
- September 10, 2014Anylan Center at Yale School of Medicine, New Haven, CT
- June 23, 2014San Diego, California
- Growing Connecticut's Bioscience Community: Supporting Ideas, Creating ValueJune 5, 2014Anlyan Center at Yale, New Haven, Connecticut
- April 29, 2014Yale School of Medicine, New Haven, Connecticut
Yale's Dr. Thomas Steitz, Nobel Prize Laureate and co-founder of Melinta, will provide introductory remarks about the the company's foundation science. This is presented by Yale University and CURE.
- April 9, 2014University of New Haven, New Haven, Connecticut
Cantor Colburn partner Todd Garabedian, Ph.D., will speak on patent law and intellectual property to engineering students at the University of New Haven's the Alvine Engineering Professional Effectiveness and Enrichment Program Speaker Series.
- March 25, 2014Yale School of Medicine, New Haven, Connecticut
Cantor Colburn partner Anne Maxwell, Ph.D., joins a CURE panel discussion of the Association for Molecular Pathology v. Myriad Genetics decision and its impact on entrepreneurship In diagnostics and customized medicines at the Yale School of Medicine in New Haven on Tuesday, March 25, from 4-6 PM. This BioHaven seminar has convened a panel of experts from various sectors of the biotech and pharmaceutical industry to discuss the business implications of cases such as Myriad.
- December 3, 2013New Haven, Connecticut
Connecticut's bioscience community celebrates the holidays together at CURE's annual holiday party. CURE (Connecticut United for Research Excellence) is the bioscience cluster of Connecticut, a diverse network of small and large life and health care sciences companies, universities, scientists, educators, students, entrepreneurs, mentors, business experts, and investors.
- CURE Funding for InnovationNovember 6, 2013New Haven, Connecticut
American Bar Association
American Chemical Society
American Intellectual Property Law Association
Intellectual Property Owners Association
Connecticut Bar Association
Connecticut Intellectual Property Law Association
Massachusetts Bar Association